Drug ID:Drug104
Drug Name:CP-461
CID:6445781
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NULL
Molecular Formula:C25H22ClFN2O
Molecular Weight:420.9 g/mol
Isomeric SMILES:CC\\1=C(C2=C(/C1=C\\C3=CC=NC=C3)C=CC(=C2)F)CC(=O)NCC4=CC=CC=C4.Cl
Synonyms:CP 461; CP-461; 227619-96-7; OSI 461; OSI-461; 68OJX9I7DT; CP 461 [WHO-DD]; 1H-Indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-(4-pyridinylmethylene)-, monohydrochloride, (1Z)-; 1H-INDENE-3-ACETAMIDE, 5-FLUORO-2-METHYL-N-(PHENYLMETHYL)-1-(4-PYRIDINYLMETHYLENE)-, HYDROCHLORIDE (1:1), (1Z)-; CEL 031
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt890 6445781 Cp-461 246 ALOX15 Homo sapiens (human) 16166323 (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in increased expression of ALOX15 protein|(5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in increased expression
dt891 6445781 Cp-461 836 CASP3 Homo sapiens (human) 11051267 (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in increased activity of CASP3 protein
dt892 6445781 Cp-461 595 CCND1 Homo sapiens (human) 15475462 (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride promotes the reaction [3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid results in decreased expression of CCND1 mrna]|(5-fluoro-2-methyl-1-(4-pyridyl)methylen
dt893 6445781 Cp-461 1026 CDKN1A Homo sapiens (human) 15475462 (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in increased expression of CDKN1A protein|(5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride promotes the reaction [3,7,11,1
dt894 6445781 Cp-461 1499 CTNNB1 Homo sapiens (human) 12392815 (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in decreased expression of CTNNB1 protein
dt895 6445781 Cp-461 6416 MAP2K4 Homo sapiens (human) 11051267 (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in increased phosphorylation of and results in increased activity of MAP2K4 protein
dt896 6445781 Cp-461 5599 MAPK8 Homo sapiens (human) 11051267 (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in increased activity of MAPK8 protein|8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [(5-fluoro-2-methyl-1-(4-pyridyl)
dt897 6445781 Cp-461 5138 PDE2A Homo sapiens (human) 11602670 (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride binds to and results in decreased activity of PDE2A protein
dt898 6445781 Cp-461 8654 PDE5A Homo sapiens (human) 11602670 (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride binds to and results in decreased activity of PDE5A protein
dt899 6445781 Cp-461 5592 PRKG1 Homo sapiens (human) 11602670 (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride results in increased expression of PRKG1 protein

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
No data available

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

No related literature

You can run management commands to establish drug-literature associations